건강 · MelanomaModerna and Merck Say One-Person Vaccine Keeps Deadliest Skin Cancer From Coming Back작성 2026년 9월 7일 오후 9:22 UTC시청방송 전문0:00A vaccine built for one person's tumor0:02just cut melanoma's comeback. More than0:041,000 high-risk patients tested a0:06personalized mRNA shot plus Keytruda0:08against the deadliest skin cancer inside0:11a country where more than a million0:12people live with melanoma, and Wall0:14Street priced a breakthrough in hours.0:16Will the full data prove it extends life0:18long enough to win approval as soon as0:19next year? On August 19th, 2026, [music]0:23Moderna and Merck said a late-stage0:25phase 3 trial of a personalized mRNA0:27therapy given with the standard [music]0:29immunotherapy Keytruda pembrolizumab cut0:32the risk that high-risk advanced0:33melanoma would recur or spread, lengthen0:36the time patients lived [music] without0:37recurrence or metastasis, and looked0:39better than Keytruda alone. The result0:42comes from company topline statements0:43reported across outlets between August0:4519 and 20, not a published paper.0:48Melanoma is the most serious and0:50deadliest [music] form of skin cancer.0:51The trial focused on the narrowest,0:53highest-stakes group, more than 1,0000:55patients,0:56>> [music]0:56>> described elsewhere as just over 1,000,0:58all with advanced high-risk disease1:00where recurrence after surgery and1:02adjuvant immunotherapy remains common,1:04whether locally in lymph nodes or as1:06distant metastasis. That group sits1:08inside a much larger population of more1:10than 1 million Americans living with or1:12previously diagnosed with melanoma. The1:14comparison was not placebo alone. It was1:16combination versus the commonly used1:18drug Keytruda alone added to standard1:20immunotherapy. The technology is the1:22story, about 10 years in the making,1:24around a decade of development. The1:26vaccine [music] is custom built for one1:28person's tumor. It reads the genetic1:30material of that tumor, identifies1:32abnormal proteins [music] displayed on1:34the surface of its cancer cells, and1:36trains the immune system to hunt cells1:37carrying that exact signature.1:39That individualization is the scientific1:41mechanism and the logistical hurdle. One1:44batch per patient, not one batch for1:46everyone. What was disclosed is narrow.1:48Only a topline summary was released. No1:50full data set, no magnitude of benefit,1:53no hazard ratios for recurrence-free or1:55metastasis-free survival, no absolute1:57risk reduction, no overall survival1:59impact, no durability data, and no2:01safety or tolerability details for the2:03combination versus Keytruda alone. It2:05has not been published, has not been2:07peer-reviewed, and the Food and Drug2:09Administration has not weighed in on2:10efficacy or safety. The companies said2:13they are sharing data with the FDA, and2:15the FDA has agreed to fast-track review2:16[music]2:17now underway, but no approval timeline2:19has been provided. The companies are2:21optimistic about market availability as2:23soon as next year in 2027 pending FDA2:26approval [music] and publication. That2:28date is an expectation, not an2:29authorization. Markets treated the2:31topline as a potential inflection point2:33for mRNA beyond infectious disease and2:35[music] for Merck's oncology franchise.2:38On Wednesday, August 19th, Moderna2:40surged by almost 177%, [music]2:43nearly 177%,2:45and Merck rose about 12.5% as the top2:47Dow gainer.2:49That sharply outpaced the broad market,2:51which rose less [music] than a quarter2:52of 1% with the Dow up more than 1002:54points and the Nasdaq up about 40.2:56>> [music]2:57>> The move reflects investors pricing a2:58first successful late-stage test of a3:00personalized cancer vaccine, [music]3:02not verified clinical benefit or3:04revenue. The day's broader tape was3:06quiet by comparison. Treasury yields3:08eased after the Treasury said it would3:10double buyback operations to support3:11liquidity in longer-dated bonds, pulling3:13[music] the 30-year yield down a day3:15after it hit its highest since 2007. The3:18Treasury noted federal debt topped $403:20trillion.3:21Federal Reserve minutes from July showed3:23deepening concern [music] about3:24inflation and willingness among several3:26policymakers to raise rates if inflation3:28does not fall to 2%, drawing little3:30market reaction. Other corporate movers3:33included Marvell Technology up about 10%3:35[music] on a reported $12.2 billion3:38Google custom chip arrangement, and3:40Target up more than 4%, [music] and3:42Estee Lauder up more than 16% on3:44earnings updates with lows also moving.3:47For families, the practical stakes turn3:49on recurrence after [music] surgery and3:51drugs like Keytruda, A therapy that3:53teaches the immune system to attack the3:55private mutations of that person's tumor3:57could extend the period without3:59recurrence. And if overall survival4:01follows,4:02>> [music]4:02>> extend life. But without hazard ratios,4:05absolute numbers, how many patients4:06[music] avoid recurrence and for how4:08long, how side effects compared to4:10Keytruda alone, and without cost,4:12manufacturing [music]4:13turnaround time, and capacity to build4:15an individualized product at scale,4:17clinicians cannot judge benefit versus4:18[music] burden and the health system4:20cannot judge who gets it and how fast.4:22The next steps that matter are4:23peer-reviewed publication [music]4:25of the full phase three data set with4:26recurrence and metastasis-free survival4:28hazard ratios and [music] absolute risk4:30reduction, reporting of overall4:31survival, disclosure of safety for the4:33combination, and [music] a defined FDA4:35fast-track review timeline and approval4:37standard. Until then, this remains a4:39company-asserted signal in more than4:401,000 high-risk patients that [music] a4:4210-year tumor-specific mRNA approach4:44plus Keytruda can delay melanoma's4:46return better than Keytruda alone, with4:48the size, durability, safety, [music]4:50and approvability still undisclosed.4:53Like and follow for more stories that4:55matter.기사 읽기스토리 타임라인HeyDex짧은 영상 ↗
